Drug Discovery & beyond

Connect with us

For data partners

Product

Resources

TRAVERSE

Data insights

info@traverse.health
+31 6 4186 7545

Cookies managing

Cookie Settings

Cookies necessary for the correct operation of the site are always enabled.
Other cookies are configurable.

Essential cookies

Always On. These cookies are essential so that you can use the website and use its functions. They cannot be turned off. They're set in response to requests made by you, such as setting your privacy preferences, logging in or filling in forms.

Analytics cookies

Disabled

These cookies collect information to help us understand how our Websites are being used or how effective our marketing campaigns are, or to help us customise our Websites for you. See a list of the analytics cookies we use here.

Advertising cookies

Disabled

These cookies provide advertising companies with information about your online activity to help them deliver more relevant online advertising to you or to limit how many times you see an ad. This information may be shared with other advertising companies. See a list of the advertising cookies we use here.

Drug discovery & beyond

Product

Main

Drug Discovery & beyond

While RWE is becoming increasingly valuable in clinical practice and regulatory decision-making we see adoption of RWE usage across the entire drug development pipeline, including new applications of the existing molecules and expanding labels to minor or underserved patient populations.

Overall, the recent advances in data generation, standardization and analysis are bringing us closer to the world where new treatments will be produced “ex situ”, without involvement of humans and living organisms and at the speed of though or even faster.

Target identification and validation

RWD can be used to identify potential disease targets and to validate existing targets through the analysis of large-scale patient data.

Drug repurposing

Label expansion is one of the most proliferate use case for real world data in drug development. With perhaps some of the most famous examples from Flatiron and Pfizer in use of Palbociclib in male breast cancer patients. Overall, real world data is essential when it comes to label expansion specifically in areas with rare diseases or small / patient populations and, hence, too costly economically to run a proper RCT.

Drug repositioning

Drug discovery is a very costly and time-consuming process and at best only 20% of clinical trials are successful, with this figure as low as 10% in Oncology and some other TAs.

With artificial intelligence and machine learning we have got the chance to increase these numbers and give molecules and substances a second chance. This is especially important since many of the failed drugs have proven to be safe and looking into applications beyond original label will save us significant resources.